Keywords
Cyclophosphamide, GVHD, GVHD prevention
Disciplines
Pharmacology
Abstract
Cyclophosphamide's lack of hematopoietic stem cell toxicity and its unique effects on the immune system have prompted several investigators to explore its potential for the prevention of graft-versus-host disease (GVHD). In haploidentical hematopoietic stem cell transplants, post-transplant cyclophosphamide together with standard prophylaxis reduces the incidence of GVHD to acceptable rates without the need for T cell depletion. In matched related and unrelated donor settings, cyclophosphamide alone has produced encouraging results. In particular, the low incidence of chronic GVHD is noteworthy. Here, we present a review of the current understanding of the mechanism of action of post-transplant cyclophosphamide and summarize the clinical data on its use for the prevention of GVHD.
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
Original Citation
Al-Homsi, A. S., Roy, T. S., Cole, K., Feng, Y., & Duffner, U. (2015). Post-Transplant High-Dose Cyclophosphamide for the Prevention of Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 21(4), 604–611. https://doi.org/10.1016/j.bbmt.2014.08.014
ScholarWorks Citation
Al-Homsi, Ahmad Samer; Roy, Tara S.; Cole, Kelli; Feng, Benjamin; and Duffner, Ulrich, "Post-Transplant High-Dose Cyclophosphamide for the Prevention of Graft-versus-Host Disease" (2014). Peer Reviewed Articles. 78.
https://scholarworks.gvsu.edu/bms_articles/78
